Novo Nordisk A/s
Q4 2022 Earnings Call
Feb 01, 2023, 7:00 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Good day, and thank you for standing by. Welcome to the Q4 2022 Novo Nordisk A/S earnings conference call. [Operator instructions] I would now like to turn the conference over to your speaker today, Lars Fruergaard Jorgensen, CEO. Please go ahead.
Lars Fruergaard Jorgensen -- President and Chief Executive Officer
Thank you, operator. Welcome to Novo Nordisk's earnings call for the full year of 2022 and the outlook for 2023. My name is Lars Fruergaard Jorgensen, and I'm the CEO of Novo Nordisk. With me today, I have executive vice president and head of commercial strategy and corporate affairs, Camilla Sylvest; executive vice president and head of North America operations, Doug Langa; executive vice president and head of development, Martin Holst Lange; and finally, chief financial officer, Karsten Munk Knudsen.
All of us would be available for the Q&A session. Today's announcement and the slides for this call are available on our website, novonordisk.com. Please note that the call is being webcast live, and the recording will be made available on our website as well. This call is scheduled to last one hour.
Please turn to the next slide. The presentation is structured as outlined on Slide 2. Please note that all sales and operating statements would be in constant exchange rates unless otherwise specified. Please turn to Slide 3.
As always, I need to advise you that this call will contain forward-looking statements. These are subject to risks and uncertainties that could cause actual results to differ materially from expectations. For further information on the risk factors, please see announcement for the full year of 2022 and the slides prepared for this presentation. Please turn to the next slide.
In 2022, we delivered double-digit sales growth and operating profit growth, and we continue to make progress on our strategic aspirations. I would like to go through the highlights before handing over the word to my colleagues. We continue to make progress across all dimensions of purpose and sustainability. Our carbon emissions decreased by 29% compared to pre-pandemic levels in 2019, and we continue to reach even more patients and patients living with diabetes compared to last year.